InSilicoMinds - Leverage our In Silico Solutions for Small Molecules Drug Development

Small Molecules

Our in silico modeling and simulation solutions are extremely valuable for both Abbreviated New Drug Application (ANDA) and 505(b)(2) programs.

By using our computational methods, in silico modeling and simulation can help predict the behavior of a drug in the human body, identify potential safety concerns, and optimize dosing regimens. We help streamline the drug development process by reducing the need for costly and time-consuming clinical trials.

For ANDA programs, in silico modeling can be used to demonstrate bioequivalence to a reference product, while for 505(b)(2) programs, it can provide valuable information to support a new drug application. In both cases, in silico modeling and simulation can help bring safe and effective drugs to market much faster and more efficiently.

Model Informed Generic Drug Development

Our AI, Modeling & Simulation experts work closely with our clients to understand their unique scientific questions of interest and challenges. We then leverage our expertise in in silico modeling and simulation to provide the correct approach to address our customer requests.

Pharmaceutical Digitization

We have extensive expertise in modeling and simulation for a wide range of applications, including pharmaceuticals, API, and process simulations. We are skilled in developing custom models and simulations to meet specific client needs. Our team is committed to staying up-to-date with the latest developments in the field and applying cutting-edge techniques to drive innovation and optimization.

We are skilled in developing custom validated models

Formulation Optimization

Our modeling and simulation solutions for Pharmaceutical formulation optimization help develop effective and safe drug products by predicting their behavior in the human body. Our approach involves the use of advanced mathematical models to optimize drug formulations, predict their performance, and reduce the need for expensive & time-consuming experiments.

Impurity Tox Profiling

Our modeling and simulation solutions can be used to predict the toxicological profile of impurities based on their chemical structure and properties. Our approach can help optimize the drug development process and guide decision making regarding impurity control strategies.

505-b2 InSilico Support

Our modeling and simulation solutions can be used to support the development of drugs under the 505(b)(2) pathway. Our approach involves using advanced computational models to simulate the behavior of a drug in the body and predict its efficacy and safety.

Dissolution Safe Space

Optimize drug product dissolution testing with our modeling and simulation solution which reduces cost and time required for testing. Assess the rate and extent to which a drug dissolves in a specific medium in silico.

PBPK/IVIVC Modeling

PBPK/IVIVC models are used to predict the in vivo performance of a drug based on its in vitro characteristics. Our in silico solutions help optimize drug formulations and predict the effect of formulation & process changes on the drug's performance.

ADME Predictions

in Silico Prediction of ADME properties of a compound (absorption, distribution, metabolism and elimination). Our solution provides insights into potential safety issues, optimizes pharmacokinetic properties, and reduces cost and time required for R&D.

Inter-species PBPK Modeling

Inter-species PBPK models are used to predict how a drug or chemical will be distributed, metabolized, and eliminated in the bodies of different species, including humans. Our inter-species predictions allow us to understand complex interactions between drugs and the body, reduce the need for animal testing, increase speed and efficiency, improve accuracy, and increase safety or drug toxicity.

QSP Modeling

Quantitative Systems Pharmacology (QSP) is a mathematical modeling approach that integrates biological, pharmacological, and physiological knowledge to understand and predict the behavior of drugs in the body. We have used QSP models to simulate drug efficacy and safety, optimize dosing regimens, and identify biomarkers for patient stratification. Our QSP models have been increasingly used in drug development and personalized medicine to support decision-making and reduce the risk of clinical trial failures.

PopPK/PD Modeling (Non-Clinical)

PK/PD modeling and simulation can be a valuable tool for assessing the safety and efficacy of drugs or chemicals in animal populations. Our solutions can be used to estimate exposure levels and potential risks associated with the use of these substances in different animal species.

Assessment of Food Effects

Our InSilico solution simulates the impact of different food types and quantities on drug product absorption. Gain valuable insights into how to optimize formulation to minimize the impact of food and ensure efficacy.

Pop PK/PD Modeling (Clinical)

PK/PD models help identify factors that influence the pharmacokinetics of drugs or chemicals, such as age, sex, and metabolic rate. PK/PD models can be used to simulate drug disposition in various patient groups, such as pediatric, geriatric, pregnant, and diseased populations.

BE Assessment & Biowaivers

Modeling and simulation can be used as a tool to streamline the BE assessment and biowaivers process by offering cost-effectiveness, time saving, reduced variability and improved drug product design.

Dose Selection & Escalation Studies

Dose selection and escalation is a process that involves using mathematical models and simulations to determine the optimal dose of a drug for a particular patient population. Our dose selection and escalation models reduce the number of experiments needed to determine the optimal dose, provide a more accurate representation of how the drug will behave in the body, and identify potential safety issues before conducting clinical trials.

Special Populations

Our Modeling and simulation solutions can model and simulate trials in virtual populations that are extremely difficult and sensitive to access like (rare disease/pediatrics/geriatrics).Our solutions help identify potential drug safety concerns in special populations, such as children, pregnant women, and the elderly which leads to better-informed dosing decisions, trial design and increased patient safety.

XPS (coating , blending, wurster)

XPS (eXtended Particle Simulation) is a highly efficient simulation solution to better understand, control and predict pharmaceutical fluid-granular processes, to enhance efficiency and improve product quality.

InSilico Evidence & Regulatory Support

Global Regulatory bodies are increasingly accepting in silico evidence and the FDA predicts that by 2030 more than 50% of all dossier submissions will have in silico evidence supporting them. We help support our customers in communicating and reporting in silico evidence to worldwide regulatory agencies (e.g FDA, EMA, CDSCO, TGA, ANVISA, etc) . We have more than a decade of experience in submitting in silico data to regulatory agencies worldwide.

RWD / RWE

Our RWD and RWE solutions offer a way to make sense of large datasets and can be used to develop personalized treatment plans that are tailored to individual patients.

Value of in silico modeling and simulation
in Small Molecule Generics.

Optimize Drug Formulations

Identify the optimal formulation and dosage forms that leads to improved drug efficacy and patient outcomes

Reduce Cost and Time to Market

Reduce the time and costs associated with clinical trials and drug development

Improve Regulatory Submissions

Help in streamlining the approval process and reduce the risk of regulatory rejection

De-risk
R&D

In silico allows informed decision-making early, de-risking R&D

Enhance Product Lifecycle Management

Identifying opportunities for reformulation or repurposing

Small Molecules

Model Informed Generic Drug Development